
EU approves Roctavian for severe hemophilia A
On August 24, BioMarin announced that the European Union approved the conditional marketing of Roctavian (Valoctocogene roxaparvovec) gene therapy for the treatment of adults with
On August 24, BioMarin announced that the European Union approved the conditional marketing of Roctavian (Valoctocogene roxaparvovec) gene therapy for the treatment of adults with